Oncology & Cancer

Immunotherapy drug bolsters head and neck cancer treatment

A University of Cincinnati clinical trial that added an immunotherapy drug to standard of care treatment regimens has shown increased survival rates for head and neck cancer patients with intermediate risk features.

Oncology & Cancer

Study validates therapy for aggressive bladder cancer

Findings from a new study led by Yale Cancer Center researchers show enfortumab vedotin is effective in patients with muscle-invasive bladder cancer (MIBC) not eligible for cisplatin chemotherapy. The data is from Cohort ...

page 22 from 40